INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) is the most common kidney-associated neoplasm. Among them, clear cell RCC is the most frequent type, accounting for 70-80% of cases \[[@R1]\]. RCC constitutes 2-3% of human cancers, and the proportion is increasing. Worldwide, more than 350,000 people were diagnosed with RCC and 140,000 people died in 2013 \[[@R2]\]. Treatment for localized RCC is mainly surgical resection, which has a good prognosis, however, the prognosis for metastatic RCC at diagnosis remains poor. Treatments for RCC have grown more sophisticated. For example, since 2000, molecularly targeted therapies have focused on inhibition of angiogenesis, and more recently anti-PD-1 antibodies have been used to activate tumor immunity. However, the therapeutic outcomes fall short, and the 5-year survival of advanced RCC is still around 20% \[[@R3], [@R4]\]. Thus, discovery of new molecular targets and new treatment strategies for RCC are urgently required.

MicroRNA (miRNA) is a type of small non-coding RNA. It fine tunes expression of RNA transcripts (both protein coding and non-protein coding genes) in a sequence-dependent manner \[[@R5]\]. A single miRNA can control a vast number of RNA transcripts in normal and diseased cells \[[@R6]\]. Therefore, aberrantly expressed miRNAs can break down regulated RNA networks and contribute to cancer cells' development, metastasis and drug resistance \[[@R7]\].

The traditional description of miRNA function indicates that 1 strand of the miRNA duplex is incorporated into the RNA-induced silencing complex (RISC), becoming the active strand (guide strand), whereas the other strand is degraded and has no function (passenger strand or miRNA^\*^) \[[@R8]\]. However, more recent studies of miRNA biogenesis have shown that some miRNA passenger strands are functional in plant and human cells \[[@R9]\]. Analyses of our original miRNA expression signatures by RNA-sequencing revealed that some passenger strands of miRNAs were significantly downregulated in several types of cancers. Based on our signatures, we have found that some passenger strands target oncogenic genes e.g., *miR-144-5p*, *miR-145-3p*, *miR-149-3p*, *miR-150-3p* and *miR-199a/b-3p* \[[@R10]--[@R16]\].

In this study, we focused on both *miR-455-5p* (the passenger strand) and *miR-455-3p* (the guide strand) that derived from *miR-455* duplex based on miRNA expression signatures of human cancers \[[@R17]\]. Interestingly, low expression of these miRNAs was significantly associated with poor prognosis of patients with RCC (*miR-455-5p*: *p* = 0.00204 and *miR-455-3p*: *p* = 0.0254) based on cohort data in The Cancer Genome Atlas (TCGA). Here, we investigated the anti-tumor roles of these miRNAs and their respective targeted oncogenic genes in RCC pathogenesis. Our present data showed that both *miR-455-5p* and *miR-455-3p* acted as anti-tumor miRNAs in RCC cells. To identify targeted oncogenes in RCC cells, we studied 27 genes, 15 of which were regulated by *miR-455-5p* and 12 by *miR-455-3p*. We found that they were significantly associated with poor prognosis by TCGA analyses.

The involvement of miRNA passenger strands in cancer pathogenesis is a novel concept in studies of miRNA biogenesis and cancer research. Identification of the function of passenger strands will enhance our understanding of the molecular pathways underlying RCC pathogenesis.

RESULTS {#s2}
=======

Expression levels of *miR-455-5p* and *miR-455-3p* in RCC clinical specimens {#s2_1}
----------------------------------------------------------------------------

The public miRNA database (miRbase: release 21) revealed that *miR-455* is located on chromosome 9q32 and the mature sequence of *miR-455-5p* (passenger strand) was 5' -- uaugugccuuuggacuacaucg -- 3' and that of *miR-455-3p* (guide strand) was 5' - gcaguccaugggcauauacac -- 3'. We investigated the expression of *miR-455-5p* and *miR-455-3p* in clinical RCC tissues (paired cancerous and adjacent non-cancerous tissues). Expression levels of *miR-455-5p* and *miR-455-3p* were significantly downregulated in RCC tissues compared with those in noncancerous tissues (*p* = 0.0014; Figure [1A](#F1){ref-type="fig"} and [p](#F1){ref-type="fig"} = 0.0227; Figure [1B](#F1){ref-type="fig"}). Furthermore, Spearman\'s rank test showed a positive correlation between expression levels of *miR-455-5p* and *miR-455-3p* (*p* = 0.0056, R = 0.515; Figure [1C](#F1){ref-type="fig"}). To investigate the molecular mechanisms of silencing of *miR-455-5p* and *miR-455-3p* in RCC cells, A498 cells were treated with the demethylating agent \[5-aza-2'-deoxycytidine (5-aza-dC)\]. Expression of *miR-455-5p and miR-455-3p* were not dramatically elevated by 5-aza-dc treatment (data not shown).

![Expression level, clinical significance and anti-tumor function of *miR-455-5p* and *miR-455-3p* in RCC\
**(A, B)** Expression levels of *miR-455-5p* and *miR-455-3p* in RCC clinical specimens. *RNU48* was used as an internal control. **(C)** Spearman\'s rank test showed a positive correlation between the expression of *miR-455-5p* and *miR-455-3p*. **(D, E)** Low expression levels of *miR-455-5p* and *miR-455-3p* were associated with low overall survival (*p* = 0.00204 and *p* = 0.0254, respectively). **(F)** Cell proliferation was determined by XTT assays 72 h after transfection with *miR-455-5p* and *miR-455-3p*. **(G)** Cell migration was determined using wound-healing assays. **(H)** Cell invasion activity was determined using Matrigel assays. ^\*^, *p* \< 0.01. ^\*\*^, *p* \< 0.0001.](oncotarget-09-26638-g001){#F1}

A large cohort analysis (n = 506) based on the TCGA database showed that low expression levels of *miR-455-5p and miR-455-3p* were associated with poor survivals in RCC patients (*p* = 0.00204 and *p* = 0.0254; Figure [1D](#F1){ref-type="fig"} and [1E](#F1){ref-type="fig"}, respectively).

Effects of ectopic expression of *miR-455-5p* and *miR-455-3p* on RCC cells {#s2_2}
---------------------------------------------------------------------------

We performed gain-of-function studies by miRNAs transfection into 786-O and A498 cells. XTT assays revealed that cell proliferation was significantly inhibited in *miR-455-5p* and *miR-455-3p* transfectants compared with that in mock or control transfectants (Figure [1F](#F1){ref-type="fig"}). Cell migration activity was significantly inhibited in *miR-455-5p* and *miR-455-3p* transfectants in comparison with those in mock or control transfectants (Figure [1G](#F1){ref-type="fig"}). Likewise, Matrigel assays showed that cell invasion activity was significantly inhibited in *miR-455-5p* and *miR-455-3p* transfectants compared to those in mock or control transfectants (Figure [1H](#F1){ref-type="fig"}). We further investigated synergistic effects of *miR-455-5p* and *miR-455-3p* expression in RCC cells. As a result, synergistic effects were not identified in this study ([Supplementary Figures 1](#SD1){ref-type="supplementary-material"}).

Incorporation of *miR-455-5p* into the RISC in RCC cells {#s2_3}
--------------------------------------------------------

We proposed that passenger strand *miR-455-5p* may be incorporated into the RNA-induced silencing complex (RISC) and thereby have a role in regulating gene activities in cancer cells. To investigate that hypothesis, we performed immunoprecipitation with antibodies targeting Argonaute2 (Ago2), which plays an important role in the RISC. After transfection with *miR-455-5p* or *miR-455-3p*, Ago2-bound miRNAs were isolated, and we performed qRT-PCR to determine whether *miR-455-5p* and *miR-455-3p* were bound to Ago2. After transfection with *miR-455-5p* and immunoprecipitation by anti-Ago2 antibodies, *miR-455-5p* levels were significantly higher than those of mock- or miR-control-transfected cells and those of *miR-455-3p*-transfected 786-O cells ([Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}). Likewise, after *miR-455-3p* transfection, *miR-455-3p* was detected by Ago2 immunoprecipitation ([Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}).

Searching for putative targets regulated by *miR-455-5p and miR-455-3p* in RCC cells {#s2_4}
------------------------------------------------------------------------------------

We performed both *in silico* and gene expression analysis to identify genes targeted by *miR-455-5p* and *miR-455-3p* for regulation. The strategy for identification of *miR-455-5p* and *miR-455-3p* target genes is shown in Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}. First, we identified 3,041 and 3,559 genes that had putative target sites for *miR-455-5p* and *miR-455-3p* in their 3′-UTR according to the TargetScanHuman 7.0 database. Next, we narrowed down those groups to 702 and 892 genes whose expression levels were upregulated (Fold-change \> 2.5) in RCC cells using a GEO database (accession number: GSE36895). Next, we identified 55 and 33 genes that were downregulated after *miR-455-5p* and *miR-455-3p* were transfected into 786-O cell (Log~2~ ratio \< −0.5; Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

![Flow chart illustrating the analytic strategy for identifying *miR-455-5p* and *miR-455-3p* targets in RCC cells\
A total of 3,041 and 3,599 genes were putative target genes of *miR-455-5p* and *miR-455-3p* in TargetScan database analysis (release 7.0). Of those groups, 15 and 12 genes were identified as putative target genes of *miR-455-5p* and *miR-455-3p* in RCC cells, respectively.](oncotarget-09-26638-g002){#F2}

###### Putative target genes regulated by *miR-455-5p* in RCC cells

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene Symbol   Gene Name                                                                                     Conserved sites count   Poorly conserved sites count   GEO expression data\         786-O *miR-455-5p* transfection (Log~2~ ratio)   Cytoband       TCGA data OS (*p* value)
                                                                                                                                                                     Fold-Change (Tumor/Normal)                                                                   
  ------------- --------------------------------------------------------------------------------------------- ----------------------- ------------------------------ ---------------------------- ------------------------------------------------ -------------- --------------------------
  *BIRC5*       baculoviral IAP repeat containing 5                                                           0                       1                              2.728                        -0.888                                           hs\|18q11.2    2.93E-09

  *SKA1*        spindle and kinetochore associated complex subunit 1                                          0                       1                              3.751                        -0.836                                           hs\|20p11.23   1.44E-07

  *CDCA8*       cell division cycle associated 8                                                              0                       1                              3.071                        -0.547                                           hs\|17q23.2    2.93E-06

  *CENPF*       centromere protein F, 350/400kDa                                                              0                       1                              2.699                        -0.905                                           hs\|9p13.3     7.01E-05

  *DEPDC1*      DEP domain containing 1                                                                       0                       2                              2.606                        -1.076                                           hs\|9q34.11    0.000111

  *ELOVL2*      ELOVL fatty acid elongase 2                                                                   0                       1                              3.11                         -0.72                                            hs\|12p13.1    0.000146

  *TNFSF4*      tumor necrosis factor (ligand) superfamily, member 4                                          0                       1                              2.65                         -0.948                                           hs\|17q25.3    0.000257

  *CD72*        CD72 molecule                                                                                 0                       1                              3.643                        -1.117                                           hs\|17q21.2    0.000668

  *KIAA0101*    KIAA0101                                                                                      0                       2                              3.358                        -0.629                                           hs\|16p13.3    0.00258

  *PLEKHG4*     pleckstrin homology domain containing, family G (with RhoGef domain) member 4                 0                       1                              2.743                        -0.716                                           hs\|12q24.23   0.00298

  *TNIP3*       TNFAIP3 interacting protein 3                                                                 0                       1                              4.313                        -1.142                                           hs\|11q12.1    0.00339

  *FOXL1*       forkhead box L1                                                                               0                       1                              2.987                        -2.048                                           hs\|19q13.41   0.0129

  *SLC7A11*     solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11   0                       2                              2.677                        -1.518                                           hs\|12q23.2    0.0234

  *SIRPA*       signal-regulatory protein alpha                                                               0                       1                              2.737                        -1.484                                           hs\|17p11.2    0.0349

  *VCAN*        versican                                                                                      1                       1                              5.753                        -0.865                                           hs\|22q13.31   0.0467

  *IL21R*       interleukin 21 receptor                                                                       0                       1                              3.377                        -1.068                                           hs\|2q11.2     n.s.

  *HLA-DPB1*    major histocompatibility complex, class II, DP beta 1                                         0                       1                              2.781                        -0.81                                            hs\|5q31.1     n.s.

  *LAYN*        layilin                                                                                       1                       1                              2.575                        -1.356                                           hs\|17p11.2    n.s.

  *IKZF1*       IKAROS family zinc finger 1 (Ikaros)                                                          0                       1                              2.548                        -0.519                                           hs\|6p21.1     n.s.

  *SLC38A1*     solute carrier family 38, member 1                                                            0                       1                              3.365                        -1.049                                           hs\|12q13.11   n.s.

  *BRIP1*       BRCA1 interacting protein C-terminal helicase 1                                               0                       1                              2.71                         -0.519                                           hs\|22q11.21   n.s.

  *GJC1*        gap junction protein, gamma 1, 45kDa                                                          1                       0                              5.978                        -0.895                                           hs\|19q13.2    n.s.

  *IGFBP3*      insulin-like growth factor binding protein 3                                                  0                       1                              11.356                       -2.607                                           hs\|12q13.11   n.s.

  *LOX*         lysyl oxidase                                                                                 0                       2                              9.982                        -1.551                                           hs\|15q26.3    n.s.

  *EHD2*        EH-domain containing 2                                                                        0                       1                              9.206                        -2.008                                           hs\|22q13.1    n.s.

  *DIRAS2*      DIRAS family, GTP-binding RAS-like 2                                                          0                       1                              6.202                        -1.342                                           hs\|11q25      n.s.

  *LRRC25*      leucine rich repeat containing 25                                                             0                       1                              6.156                        -0.685                                           hs\|11q23.3    n.s.

  *RASSF2*      Ras association (RalGDS/AF-6) domain family member 2                                          0                       1                              6.146                        -1.364                                           hs\|Xq28       n.s.

  *GAS2L3*      growth arrest-specific 2 like 3                                                               0                       1                              5.641                        -0.73                                            hs\|17q12      n.s.

  *EGFR*        epidermal growth factor receptor                                                              0                       1                              4.5                          -1.689                                           hs\|19q13.2    n.s.

  *KRBA1*       KRAB-A domain containing 1                                                                    0                       2                              4.421                        -1.144                                           hs\|2p23.3     n.s.

  *SLC1A3*      solute carrier family 1 (glial high affinity glutamate transporter), member 3                 0                       1                              4.302                        -0.645                                           hs\|22q13.33   n.s.

  *TLR3*        toll-like receptor 3                                                                          0                       1                              4.139                        -2.606                                           hs\|5q14.3     n.s.

  *MS4A7*       membrane-spanning 4-domains, subfamily A, member 7                                            0                       1                              4.088                        -0.619                                           hs\|19p13.11   n.s.

  *PTGS1*       prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)         0                       1                              4.043                        -2.257                                           hs\|12q23.3    n.s.

  *FAM111B*     family with sequence similarity 111, member B                                                 0                       1                              3.986                        -0.996                                           hs\|17q21.32   n.s.

  *APOLD1*      apolipoprotein L domain containing 1                                                          0                       1                              3.953                        -1.385                                           hs\|6p21.1     n.s.

  *CDHR1*       cadherin-related family member 1                                                              0                       1                              3.727                        -0.574                                           hs\|7p12.2     n.s.

  *PHKA2*       phosphorylase kinase, alpha 2 (liver)                                                         0                       1                              3.661                        -0.955                                           hs\|15q15.1    n.s.

  *LRRK1*       leucine-rich repeat kinase 1                                                                  0                       1                              3.558                        -0.654                                           hs\|7q36.3     n.s.

  *PGBD5*       piggyBac transposable element derived 5                                                       0                       1                              3.516                        -1.466                                           hs\|6p24.2     n.s.

  *LCK*         LCK proto-oncogene, Src family tyrosine kinase                                                0                       1                              3.269                        -1.235                                           hs\|5p13.2     n.s.

  *HS3ST2*      heparan sulfate (glucosamine) 3-O-sulfotransferase 2                                          0                       1                              2.985                        -1.116                                           hs\|1q21.3     n.s.

  *NEURL1B*     neuralized E3 ubiquitin protein ligase 1B                                                     0                       1                              2.906                        -1.008                                           hs\|17q21.32   n.s.

  *COL8A1*      collagen, type VIII, alpha 1                                                                  0                       1                              2.88                         -1.102                                           hs\|2p22.2     n.s.

  *DIAPH2*      diaphanous-related formin 2                                                                   0                       1                              2.872                        -0.653                                           hs\|9p13.3     n.s.

  *GJA1*        gap junction protein, alpha 1, 43kDa                                                          0                       1                              2.797                        -0.658                                           hs\|12q23.2    n.s.

  *LCP1*        lymphocyte cytosolic protein 1 (L-plastin)                                                    0                       1                              2.773                        -2.022                                           hs\|2p16.2     n.s.

  *CMPK2*       cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial                                      0                       1                              2.747                        -0.963                                           hs\|5q31.1     n.s.

  *TRPV2*       transient receptor potential cation channel, subfamily V, member 2                            0                       4                              2.701                        -0.644                                           hs\|11q12.1    n.s.

  *GRAMD4*      GRAM domain containing 4                                                                      0                       1                              2.684                        -0.921                                           hs\|3q13.12    n.s.

  *SEMA6A*      sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A               0                       2                              2.61                         -1.354                                           hs\|3p21.31    n.s.

  *EDN1*        endothelin 1                                                                                  0                       1                              2.598                        -0.774                                           hs\|1p34.3     n.s.

  *TMEM140*     transmembrane protein 140                                                                     0                       1                              2.558                        -0.801                                           hs\|5q35.3     n.s.

  *LRP4*        low density lipoprotein receptor-related protein 4                                            0                       1                              2.525                        -0.96                                            hs\|6q22.31    n.s.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n.s., not significant.

###### Putative target genes regulated by *miR-455-3p* in RCC cells

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene Symbol   Gene Name                                                       Conserved sites count   Poorly conserved sites count   GEO expression data\         786-O *miR-455-3p* transfection (Log~2~ ratio)   Cytoband       TCGA data OS (*p* value)
                                                                                                                                       Fold-Change (Tumor/Normal)                                                                   
  ------------- --------------------------------------------------------------- ----------------------- ------------------------------ ---------------------------- ------------------------------------------------ -------------- --------------------------
  *TRIM36*      tripartite motif containing 36                                  0                       2                              2.822                        -1.084                                           hs\|5q22.3     1.66E-06

  *FXYD5*       FXYD domain containing ion transport regulator 5                0                       1                              4.276                        -1.377                                           hs\|19q13.12   3.60E-06

  *CENPF*       centromere protein F, 350/400kDa                                0                       1                              2.699                        -0.652                                           hs\|1q41       7.01E-05

  *NCAPG*       non-SMC condensin I complex, subunit G                          0                       1                              2.746                        -0.977                                           hs\|4p15.31    7.27E-05

  *PARVG*       parvin, gamma                                                   0                       1                              3.403                        -2.019                                           hs\|22q13.31   0.000548

  *SKA3*        spindle and kinetochore associated complex subunit 3            0                       1                              2.597                        -0.756                                           hs\|13q12.11   0.000596

  *ISG20*       interferon stimulated exonuclease gene 20kDa                    0                       1                              5.168                        -0.719                                           hs\|15q26.1    0.0014

  *PAQR4*       progestin and adipoQ receptor family member IV                  0                       1                              5.134                        -1.213                                           hs\|16p13.3    0.00152

  *COL5A1*      collagen, type V, alpha 1                                       0                       1                              3.025                        -0.547                                           hs\|9q34.3     0.00164

  *PLXDC1*      plexin domain containing 1                                      0                       2                              3.144                        -1.3                                             hs\|17q12      0.00186

  *PRR7*        proline rich 7 (synaptic)                                       0                       1                              2.503                        -0.737                                           hs\|5q35.3     0.00307

  *C10orf10*    chromosome 10 open reading frame 10                             0                       1                              3.95                         -0.59                                            hs\|10q11.21   0.0456

  *PFKP*        phosphofructokinase, platelet                                   0                       1                              5.385                        -0.511                                           hs\|10p15.2    n.s.

  *HK2*         hexokinase 2                                                    0                       1                              26.667                       -0.864                                           hs\|2p12       n.s.

  *GRIK3*       glutamate receptor, ionotropic, kainate 3                       1                       0                              6.25                         -0.818                                           hs\|1p34.3     n.s.

  *HSPG2*       heparan sulfate proteoglycan 2                                  0                       1                              5.466                        -0.572                                           hs\|1p36.12    n.s.

  *ARL11*       ADP-ribosylation factor-like 11                                 0                       1                              5.283                        -0.813                                           hs\|13q14.2    n.s.

  *CXorf36*     chromosome X open reading frame 36                              0                       2                              4.975                        -1.576                                           hs\|Xp11.3     n.s.

  *FAM57A*      family with sequence similarity 57, member A                    0                       1                              4.89                         -0.662                                           hs\|17p13.3    n.s.

  *FUT11*       fucosyltransferase 11 (alpha (1,3) fucosyltransferase)          0                       1                              4.124                        -1.519                                           hs\|10q22.2    n.s.

  *DDIT4*       DNA-damage-inducible transcript 4                               0                       1                              3.996                        -0.561                                           hs\|10q22.1    n.s.

  *PPP1R9B*     protein phosphatase 1, regulatory subunit 9B                    1                       0                              3.801                        -0.523                                           hs\|17q21.33   n.s.

  *TRIM9*       tripartite motif containing 9                                   0                       1                              3.763                        -0.878                                           hs\|14q22.1    n.s.

  *DCLK1*       doublecortin-like kinase 1                                      0                       1                              3.633                        -1.087                                           hs\|13q13.3    n.s.

  *CSF1R*       colony stimulating factor 1 receptor                            0                       1                              3.418                        -0.88                                            hs\|5q32       n.s.

  *KCNE4*       potassium voltage-gated channel, Isk-related family, member 4   0                       1                              3.368                        -0.867                                           hs\|2q36.1     n.s.

  *GPR20*       G protein-coupled receptor 20                                   0                       1                              3.196                        -1.272                                           hs\|8q24.3     n.s.

  *GPR85*       G protein-coupled receptor 85                                   0                       3                              2.918                        -0.608                                           hs\|7q31.1     n.s.

  *ADAMTS2*     ADAM metallopeptidase with thrombospondin type 1 motif, 2       0                       1                              2.862                        -0.679                                           hs\|5q35.3     n.s.

  *HLA-DPB1*    major histocompatibility complex, class II, DP beta 1           0                       1                              2.781                        -1.046                                           hs\|6p21.32    n.s.

  *BRIP1*       BRCA1 interacting protein C-terminal helicase 1                 0                       1                              2.71                         -0.996                                           hs\|17q23.2    n.s.

  *PIK3R5*      phosphoinositide-3-kinase, regulatory subunit 5                 0                       1                              2.623                        -0.594                                           hs\|17p13.1    n.s.

  *IKZF1*       IKAROS family zinc finger 1 (Ikaros)                            0                       2                              2.548                        -0.655                                           hs\|7p12.2     n.s.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n.s., not significant.

We selected 15 and 12 genes whose high expression levels were associated (*p* \< 0.05) with low overall survivals of RCC patients according to the OncoLnc database. Kaplan-Meier survival curves showed that high expression levels of 15 and 12 genes were associated with poor prognosis in RCC patients (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}, respectively). Moreover, we analyzed whether these gene sets (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) would be prognostic markers for patients with RCC. Our results showed that expression status of these gene sets were effective as prognostic markers for patients with RCC ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Patients with high gene signature expressions were significantly associated with short DFS and OS than those with low gene signature expressions (*p* \< 0.0001, [Supplementary Figures 3A-2, 3A-3, 3B-2](#SD1){ref-type="supplementary-material"} and [3B-3](#SD1){ref-type="supplementary-material"}). These findings showed that *miR-455-5p* and *miR-455-3p* regulated molecular networks were deeply involved in RCC pathogenesis and may be therapeutic targets of RCC. Genomics Analysis and Visualization Platform were used for visualization of gene expression heatmaps (<http://r2.amc.nl>) \[[@R18]\]. The normalized mRNA expression values in the RNA sequencing data were processed and provided as Z-scores.

![TCGA database analysis of putative targets of *miR-455-5p* in RCC\
Kaplan-Meier plots of overall survival with log-rank tests for 15 genes with high and low expression from the TCGA database.](oncotarget-09-26638-g003){#F3}

![TCGA database analysis of putative targets of *miR-455-3p* in RCC\
Kaplan-Meier plots of overall survival with log-rank tests for 12 genes with high and low expression from the TCGA database.](oncotarget-09-26638-g004){#F4}

We focused on spindle and kinetochore-associated complex subunits 1 and 3 (*SKA1* and *SKA3*) because we recently reported that regulation of *SKA1* by anti-tumor *miR-10a-5p* was involved in RCC pathogenesis. Both *SKA1* and *SKA3* were pivotal candidate genes targeted by *miR-455-5p* and *miR-455-3p*, respectively, and we hypothesized that the *SKA* complex was closely involved in RCC pathogenesis and could be regulated by several anti-tumor miRNAs in RCC cells.

Direct regulation of *SKA1* by *miR-455-5p* and *SKA3* by *miR-455-3p* in RCC cells {#s2_5}
-----------------------------------------------------------------------------------

Both mRNA and protein expression levels of *SKA1*/SKA1 were reduced by ectopic expression of *miR-455-5p* in 786-O and A498 cells (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). The TargetScan database shows that the *SKA1* gene has a single target site for *miR-455-5p* in its 3'-UTR region (Figure [5C](#F5){ref-type="fig"}). No target site for *miR-455-3p* was detected by the TargetScan database. Luminescence intensity was significantly reduced by co-transfection with *miR-455-5p* and the vector carrying the wild-type 3′-UTR of *SKA1* (Figure [5D](#F5){ref-type="fig"}). Conversely, luminescence intensity was not reduced when the target site of *miR-455-5p* was deleted from the vectors (Figure [5D](#F5){ref-type="fig"}).

![Regulation of *SKA1* expression by *miR-455-5p* in RCC cells\
**(A)** Expression levels of *SKA1* mRNA 48 h after transfection of 10 nM *miR-455-5p* into cell lines. *GUSB* was used as an internal control. **(B)** Protein expression of SKA1 72 h after transfection of *miR-455-5p*. GAPDH was used as a loading control. **(C)** *miR-455-5p* binding sites in the 3′-UTR of *SKA1* mRNA. **(D)** Dual luciferase reporter assays using vectors encoding putative *miR-455-5p* target sites (positions 854--861) in the *SKA1* 3′-UTR for both wild-type and deleted regions. Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities. ^\*^, *p* \< 0.0001. ^\*\*^, *p* \< 0.01.](oncotarget-09-26638-g005){#F5}

In Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}, the expression levels of *SKA3*/SKA3 were reduced by ectopic expression of *miR-455-3p* in 786-O and A498 cells. A single binding site for *miR-455-3p* is annotated by the TargetScan database in the 3'-UTR region of *SKA3*. However, no binding site for *miR-455-5p* was observed in the 3'-UTR region of *SKA3* (Figure [6C](#F6){ref-type="fig"}). Luciferase reporter assays showed that luminescence intensity was significantly reduced by co-transfection with *miR-455-3p* and the vector carrying the wild-type 3′-UTR of *SKA3* (Figure [6D](#F6){ref-type="fig"}).

![Regulation of *SKA3* expression by *miR-455-3p* in RCC cells\
**(A)** Expression levels of *SKA3* mRNA 48 h after transfection of 10 nM *miR-455-3p* into cell lines. *GUSB* was used as an internal control. **(B)** Protein expression of SKA3 72 h after transfection with *miR-455-3p*. GAPDH was used as a loading control. **(C)** *miR-455-3p* binding sites in the 3′-UTR of *SKA3* mRNA. **(D)** Dual luciferase reporter assays using vectors encoding putative *miR-455-5p* target sites (positions 1495--1501) in the *SKA3* 3′-UTR for both wild-type and deleted regions. Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities. ^\*^, *p* \< 0.0001. ^\*\*^, *p* \< 0.01.](oncotarget-09-26638-g006){#F6}

Unexpectedly in these analyses, expression of *SKA1*/SKA1 was reduced by *miR-455-3*p restoration (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). Likewise, expression of *SKA3*/SKA3 was affected by *miR-455-5*p restoration (Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Based on these data, we proposed that the destruction of SKA1 affects SKA3, and the destruction of SKA3 affects SKA1. To verify this hypothesis, we conducted experiments using si-*SKA1* and si-*SKA3* in RCC cells. Our data showed that the expression levels of *SKA1* were reduced by si-*SKA3* transfection ([Supplementary Figure 4A](#SD1){ref-type="supplementary-material"}). Similarly, expression of *SKA3* was reduced by si-*SKA1* transfection ([Supplementary Figure 4B](#SD1){ref-type="supplementary-material"}). From this analysis it became clear that the expression of *SKA1* and *SKA3* mutually influenced each other.

SKA family consists of SKA1, SKA2 and SKA3. In addition, we investigated whether expression of SKA1 or SKA3 affected the expression of SKA2 in RCC cells. Furthermore, expression of *SKA2* was reduced by si-*SKA1* or si-*SKA3* transfection ([Supplementary Figure 4C](#SD1){ref-type="supplementary-material"} and [4D](#SD1){ref-type="supplementary-material"}).

Effects of silencing *SKA3* in RCC cells {#s2_6}
----------------------------------------

We performed loss-of-function experiments using si-*SKA3* (si-*SKA3*\_1 and si-*SKA3*\_2) transfection into 786-O and A498 cells to investigate the functional significance of *SKA3* in RCC cells. We demonstrated that the expression levels of *SKA3* mRNA and SKA3 protein were significantly reduced in qRT-PCR and Western blotting analyses (Figure [7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). Furthermore, functional assays showed that si-*SKA3* transfection significantly inhibited cell proliferation, migration, and invasion in comparison with mock- or si-control-transfected cells (Figure [7C-7E](#F7){ref-type="fig"}).

![Effects of *SKA3* silencing in RCC cell lines\
**(A)** *SKA3* mRNA expression 48 h after transfection with 10 nM si-*SKA3* into RCC cell lines. *GUSB* was used as an internal control. **(B)** SKA3 protein expression 72 h after transfection with si-*SKA3*. GAPDH was used as a loading control. **(C)** Cell proliferation was determined with XTT assays 72 h after transfection of 10 nM si-*SKA3*\_1 or si-*SKA3*\_2. **(D)** Cell migration activity. **(E)** Cell invasion activity. ^\*^, *p* \< 0.0001. ^\*\*^, *p* \< 0.001.](oncotarget-09-26638-g007){#F7}

Expression of *SKA3* in RCC clinical tissues {#s2_7}
--------------------------------------------

A total of 15 pairs of RCC tissues plus adjacent noncancerous tissues and RCC cell lines were used to validate the mRNA expression level of *SKA3* by qRT-PCR. Expression of *SKA3* was significantly upregulated in RCC tissues compared with those in adjacent noncancerous tissues (*p* = 0.0253; Figure [8A](#F8){ref-type="fig"}). Furthermore, we performed immunohistochemistry with an RCC tissue microarray (cat. no. KD806; US Biomax, Rockville, MD, USA). Patient characteristics for samples used in the tissue microarray are described in <http://www.biomax.us/tissue-arrays/Kidney/KD806>. SKA3 protein was strongly expressed in several cancer lesions whereas it was rarely expressed in normal lesions (Figure [8B](#F8){ref-type="fig"}).

![Expression of *SKA3* in clinical specimens of RCC\
**(A)** Expression levels of *SKA3* in RCC clinical specimens. *GUSB* was used as an internal control. **(B)** Immunostaining showed that SKA3 was strongly expressed in several cancer lesions compared with normal lesions (100× and 400× magnification field).](oncotarget-09-26638-g008){#F8}

Effects of co-transfection of *SKA3* and *miR-455-3p* in RCC cells {#s2_8}
------------------------------------------------------------------

We investigated *SKA3* rescue studies in 786-O cells to elucidate whether the molecular pathway of *SKA3*/*miR-455-3p* was significant for RCC progression. SKA3 protein expression by Western blotting analysis is shown in Figure [9A](#F9){ref-type="fig"}. Functional assays showed that the proliferation, migration and invasive abilities of RCC cells were significantly recovered by *SKA3* and *miR-455-3p* transfection compared with cells with restored *miR-455-3p* only (Figure [9B-9D](#F9){ref-type="fig"}). These results suggested that *SKA3* had a pivotal role in RCC progression.

![Effects of co-transfection of *SKA3/miR-455-3p* into 786-O cells\
**(A)** SKA3 protein expression was evaluated by Western blotting analysis of 786-O cells 72 h after reverse transfection with *miR-455-3p* and 48 h after forward transfection with the *SKA3* vector. GAPDH was used as a loading control. **(B)** Cell proliferation was determined using XTT assays 72 h after reverse transfection with *miR-455-3p* and 48 h after forward transfection with the *SKA3* vector. **(C)** Cell migration activity was assessed by wound-healing assays 48 h after reverse transfection with *miR-455-3p* and 24 h after forward transfection with the *SKA3* vector. **(D)** Cell invasion activity was characterized by invasion assays 48 h after reverse transfection with *miR-455-3p* and 24h after forward transfection with *SKA3* vector. ^\*^, *p* \< 0.0001.](oncotarget-09-26638-g009){#F9}

Clinical significance of the SKA complex in RCC based on TCGA database {#s2_9}
----------------------------------------------------------------------

To validate the clinical significance of SKA complex subunits 1,2 and 3 in RCC pathogenesis, we asked whether the expression levels of *SKA1*, *SKA2* and *SKA3* were associated with the duration of disease-free survival (DFS) in RCC patients. As shown in Figure [10A](#F10){ref-type="fig"}, high expression levels of *SKA1* and *SKA3* were significantly associated with low DFS in RCC patients. Next, we analyzed the relationships among *SKA1*, *SKA2* and *SKA3* expression and disease stage and histological grade in RCC. *SKA1* and *SKA3* expression levels were significantly increased in the more advance tumor stage and histological grade (Figure [10B](#F10){ref-type="fig"} and [10C](#F10){ref-type="fig"}). We further investigated the clinical significance and expression status of *miR-455-5p*/*SKA1* and *miR-455-3p*/*SKA3* in the patients with RCC. Kaplan-Meier analyses showed that low expression of *miR-455-5p*/high expression of *SKA1* group was significantly poor prognosis compared with high expression of *miR-455-5p*/low expression of *SKA1* group by TCGA datasets ([Supplementary Figure 5A](#SD1){ref-type="supplementary-material"}). In a similar manner, low expression of *miR-455-3p*/high expression of *SKA3* group was predicted poor prognosis compared with high expression of *miR-455-3p*/low expression of *SKA3* group by TCGA datasets ([Supplementary Figure 5B](#SD1){ref-type="supplementary-material"}).

![Relationships between expression levels of *SKA1, SKA2* and *SKA3* and disease-free survival, tumor stage and histological grade\
All patients' data were obtained from TCGA database. **(A)** Kaplan-Meier survival curves for disease-free survival based on *SKA1, SKA2* and *SKA3* expression in patients with RCC. **(B, C)** Relationships between expression levels of *SKA1, SKA2* and *SKA3* and disease stage and histological grade. ^\*^, *p* \< 0.01. ^\*\*^, *p* \< 0.001. ^\*\*\*^, *p* \< 0.0001.](oncotarget-09-26638-g010){#F10}

We performed univariable and multivariable Cox hazard regression analysis to investigate the clinical significance of *SKA1* and *SKA3* expression together with other clinical factors for overall survival in RCC patients. After multivariate analysis, high *SKA1* and *SKA3* expression levels, age, tumor stage and histological grade were independent predictive factors for overall survival (hazard ration (HR) = 1.48, *p* = 0.0134, HR = 1.53, *p* = 0.0073, HR = 2.75, *p* \< 0.0001 and HR = 1.67, *p* = 0.004, respectively; Table [3](#T3){ref-type="table"}). These results suggested that high expression of *SKA1 and SKA3* is closely associated with cancer progression and the patient\'s prognosis in RCC.

###### Univariable and multivariable Cox hazard regression models for overall survival in RCC patients

  Variables                      Group               HR     Univariable   Multivariable                      
  ------------------------------ ------------------- ------ ------------- --------------- ------ ----------- -----------
  *SKA1* and *SKA3* expression   both high / other   2.04   1.51-2.75     \< 0.0001       1.48   1.09-2.02   0.0134
  Age                            ≥60 / \<60          1.81   1.33-2.50     0.0001          1.53   1.12-2.12   0.0073
  Gender                         Male / Female       0.96   0.71-1.32     0.804           \-     \-          \-
  Stage                          III+IV / I+II       3.74   2.74-5.16     \< 0.0001       2.75   1.97-3.90   \< 0.0001
  Histlogical grade              G3+4 / G1+2         2.61   1.87-3.70     \< 0.0001       1.67   1.17-2.42   0.004

DISCUSSION {#s3}
==========

Due to recently developed molecularly targeted drugs, RCC treatment outcomes have improved. However, the appearance of drug-resistant cancer cells during the course of treatment is a major obstacle in continued therapy \[[@R19]\]. Discovery of molecular targets for resistant cancer cells has occupied an important position in the development of the latest cancer therapies. To discover novel targets for RCC treatment, we have identified several anti-tumor miRNAs that regulate oncogenic targets in RCC cells, including *miR-26a*, *miR-26b*, *miR-29*a, *miR-29b*, *miR-29c*, *miR-101-3p* and *miR-10a-5p* \[[@R17], [@R20]--[@R22]\]. Our studies revealed that ubiquitin-like with PHD and ring finger domains 1 (*UHRF1*) was directly regulated by *miR-101-3p* and overexpression of *UHRF1* was observed in sunitinib-treated RCC tissues \[[@R17]\]. It was reported that 2 genes (lysyl oxidase-like 2 (*LOXL2*) and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (*PLOD2*)) were direct targets of the *miR-29*-family and *miR-26a*/*miR-26b*, respectively. Overexpression of these genes enhanced cancer cell migration and invasive abilities \[[@R20]\]. More recently, the gene encoding spindle and kinetochore associated protein 1 (*SKA1*) was identified as a target of anti-tumor *miR-10a-5p*. Overexpression of *SKA1* was detected in clinical specimens from patients treated with tyrosine kinase inhibitors and its expression contributed to cancer cell aggressiveness \[[@R22]\]. Interestingly, high expression of 4 genes targeted by anti-tumor miRNAs was significantly associated with poor prognosis of patients with RCC according to TCGA database analyses (*UHRF1*: *p* = 4.87E-06, *LOXL2*: *p* = 0.0343, *PLOD2*: *p* = 0.000855 and *SKA1*: *p* = 1.44E-07). These findings indicate that our miRNA-based approaches effectively identify molecular targets for RCC treatments.

Our recent studies showed that some miRNA passenger strands (*miR-144-5p*, *miR-145-3p*, *miR-149-3p*, *miR-150-3p* and *miR-199a/b-3p*) acted as anti-tumor miRNAs through their targeting of oncogenic genes in several cancers \[[@R10], [@R12]--[@R14], [@R16]\]. Our data represent an exception to the general concept of miRNA biogenesis and may offer new approaches to miRNA analysis. It has been reported by other research groups that passenger strands of miRNAs were functional in cancer cells. For examples, *miR-149-3p* inhibited cancer aggressiveness and metastasis in breast cancer \[[@R23]\]. Furthermore, *miR-21-3p* functions as a tumor suppressor via targeting methionine adenosyltransferase (*MAT*) in hepatocellular carcinoma \[[@R24]\]. In clear cell RCC, the *miR-514a-3p* expression level was significantly downregulated and behaves as a tumor suppressor through its targeting of epidermal growth factor receptor (*EGFR*) \[[@R25]\].

In RCC cells, we identified a total of 55 oncogenes that were putative targets of *miR-455-5p* and 33 that were likely targets of *miR-455-3p* (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Among them, several genes have been reported to be involved in RCC pathogenesis. *KIAA0101* induced by erythropoietin, promoted cancer proliferation and migration, and higher expression of *KIAA0101* was associated with a poorer prognosis in RCC \[[@R26]\]. *VCAN* was overexpressed in clear cell RCC tissues and high expression of the gene was associated with metastasis and poorer survival after nephrectomy \[[@R27]\]. *PARVG* was also reported to be highly associated with RCC prognosis \[[@R28]\]. Furthermore, our research groups have revealed that *CENPF*, directly regulated by *miR-205-5p*, was overexpressed and involved in prostate cancer pathogenesis \[[@R29]\]. These target genes represent potential therapeutic targets for RCC. Our data suggested that both strands of *miR-455* duplex controlled several types of genes which contributed to cancer cell proliferation, invasion and migration. Thus, the elucidation of genes directly regulated by anti-tumor *miR-455* significantly help our understanding of pathogenesis in RCC.

Here, we focused on the SKA complex, which is a sub-complex of the outer kinetochore and attaches to spindle microtubules to maintain the metaphase plate during mitosis. The structure of the SKA complex is a coiled dimer formed by interaction between SKA1, SKA2 and SKA3 proteins \[[@R30]\]. Among them, C-terminal domains of SKA1 and SKA3 were especially important for microtubule binding and mitotic progression \[[@R30]--[@R32]\]. The SKA complex likely plays a pivotal role in the onset of anaphase in mitosis \[[@R33]\]. In cancer cells, including RCC, genes that regulate the cell cycle can mutate and produce excessive growth \[[@R34]\].

Our previous study showed overexpression of SKA1 in RCC clinical specimens, and its expression was associated with poor prognosis of RCC patients \[[@R22]\]. In this study, we demonstrated that expression of *SKA3* significantly contributed to RCC pathogenesis. Other studies showed that overexpression of *SKA1* and *SKA3* was related to cancer aggressiveness in several other cancers, including non-small cell lung cancer, prostate cancer, bladder cancer, gastric cancer, colorectal cancer and adenoid cystic carcinoma \[[@R35]--[@R40]\]. Previous study showed that overexpression of SKA2 was observed in breast cancer and lung cancer specimens and its expression was enhanced to cancer cell proliferation \[[@R41]\]. Interestingly, several oncogenic signaling pathways, including ERK1/2, AKT, FAK and SRC, are regulated by expression of *SKA1* in cancer cells \[[@R22]\]. These findings indicate that a member of the SKA complex might be a therapeutic target for RCC treatment.

In conclusions, both strands of the *miR-455* duplex, *miR-455-5p* and *miR-455-3p*, acted as anti-tumor miRNAs through their targeting of several oncogenes in RCC. Genome-wide gene expression analyses and *in silico* approaches revealed that *SKA1* and *SKA3* were regulated by these miRNAs. Overexpression of *SKA1* and *SKA3* was involved in RCC pathogenesis, and these molecules might be potential prognostic markers and therapeutic targets for RCC. Involvement of passenger strands of miRNAs in cancer pathogenesis is a novel concept that provides new approaches to the treatment of RCC pathogenesis.

MATERIALS AND METHODS {#s4}
=====================

Clinical specimen collection, cell lines and cell culture {#s4_1}
---------------------------------------------------------

We collected tissues from 15 patients who were diagnosed with renal tumors and who underwent radical nephrectomy at Chiba University Hospital (Chiba, Japan) between 2012 and 2015. Table [4](#T4){ref-type="table"} shows clinicopathological features of the 15 patients. All patients were diagnosed with clear cell carcinoma. Prior to surgery, all patients agreed that their own specimens would be used for research and they signed informed consent documents. We used 2 human RCC cell lines (786-O and A498) obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) as previously described \[[@R29], [@R42], [@R43]\]. The 2 cell lines were cultured in RPMI1640 with 10% fetal bovine serum (FBS) (HyClone, Utah, USA).

###### Characteristics of 15 patients with clear cell RCC

  No.   Age   Gender   Grade          pT    INF   v   ly   e.g or ig   fc   im   rc   rp   s
  ----- ----- -------- -------------- ----- ----- --- ---- ----------- ---- ---- ---- ---- ---
  1     65    F        G1\>G2         T1a   a     0   0    e.g         1    0    0    0    0
  2     59    M        G3\>G2         T1b   a     0   0    e.g         1    0    0    0    0
  3     70    M        G2\>G3\>G1     T1a   a     0   0    e.g         1    0    0    0    0
  4     52    M        G2\>G3         T1b   a     0   0    e.g         1    1    0    0    0
  5     76    F        G2\>G3         T3a   a     1   0    e.g         1    0    0    0    0
  6     64    M        G2\>G3\>G1     T3a   b     1   0    ig          0    1    1    0    0
  7     67    M        G2\>G3\>G1     T3a   b     1   0    ig          1    0    0    0    0
  8     59    M        G3             T3a   b     1   0    ig          0    0    0    0    0
  9     77    M        G1\>G2         T1b   a     0   0    e.g         1    0    0    0    0
  10    51    F        G2\>G1\>G3     T3a   b     1   0    ig          0    0    0    0    0
  11    51    M        G2\>G1         T1b   a     0   0    e.g         0    0    0    0    0
  12    78    M        G2\>G1\>\>G3   T1b   b     0   0    e.g         1    0    0    0    0
  13    57    M        G2             T1b   a     0   0    e.g         0    0    0    0    0
  14    54    M        G2\>G1         T3a   a     0   0    e.g         0    0    1    0    0
  15    74    F        G3             T3a   b     1   0    e.g         0    0    0    1    1

F, female; M, male; INF, infiltration; v, vein; ly, lymph node; e.g, expansive growth; ig, infiltrative growth; fc, capsular formation; im, intrarenal metastasis; rc, renal capsule invasion; rp, pelvis invasion; s, sinus invasion.

Transfection of mature miRNA, siRNA or plasmid vectors into RCC cells {#s4_2}
---------------------------------------------------------------------

The following mature miRNA species were used in this study: mature miRNA and Pre-miR miRNA Precursors (*hsa-miR-455-5p*; P/N: PM10529 and *hsa-miR-455-3p*; P/N: PM11142; from Applied Biosystems, Foster City, CA, USA). The following siRNAs were used: Stealth Select RNAi siRNA, si-*SKA3* (HSS137458 and HSS176800; Invitrogen, Carlsbad, CA, USA), and negative control miRNA/siRNA (P/N: AM17111; Applied Biosystems). *SKA3* plasmid vectors were designed and created by Kazusa DNA Research Institution (Product ID: FHC28197; Kisarazu, Japan). miRNAs and siRNAs were incubated with Opti-MEM (Invitrogen) and Lipofectamine RNAiMax transfection reagents (Invitrogen), as previously described \[[@R29], [@R42], [@R43]\]. Plasmid vectors were incubated with Opti-MEM and Lipofectamine 3000 reagents (Invitrogen) by forward transfection with the manufacturer\'s protocol.

Incorporation of *miR-455-5p* or *miR-455-3p* into the RISC {#s4_3}
-----------------------------------------------------------

786-O cells were transfected with 10 nM miRNA by reverse transfection. After 48 h, immunoprecipitation was performed using a human Ago2 miRNA isolation kit (Wako, Osaka, Japan) with the manufacturer\'s protocol. Expression levels of *miR-455-5p* or *miR-455-3p* were determined by qRT-PCR. The expression data were normalized to the expression of *miR-26a* (product ID: 000404; Applied Biosystems), which was not influenced by either *miR-455-5p* or *miR-455-3p* transfection.

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) {#s4_4}
--------------------------------------------------------------------------------

Total RNA was extracted with TRIzol reagent (Invitrogen) according to the manufacturer\'s protocol, as described previously \[[@R29], [@R42], [@R43]\]. The procedure for PCR quantification was described previously \[[@R29], [@R42], [@R43]\]. Expression levels of *miR-455-5p* (Assay ID: 001280) and *miR-455-3p* (Assay ID: 002244) were determined by TaqMan qRT-PCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to *RNU48* expression (assay ID: 001006; Applied Biosystems). TaqMan probes and primers for *SKA1* (P/N: Hs00536843_m1; Applied Biosystems), *SKA3* (P/N: Hs00384927_m1; Applied Biosystems), *GAPDH* (an internal control; P/N: Hs02758991_m1; Applied Biosystems) and *GUSB* (an internal control; P/N: Hs00939627_ml; Applied Biosystems) were assay-on-demand gene expression products.

Cell proliferation, migration and invasion assays {#s4_5}
-------------------------------------------------

Cell proliferation assays were carried out with XTT protocols, migration was assessed by wound-healing assays and invasion assays were carried out with Matrigel-coated Boyden chambers, as previously described \[[@R29], [@R42], [@R43]\].

Identification of putative target genes regulated by *miR-455-5p* and *455-3p* in RCC cells {#s4_6}
-------------------------------------------------------------------------------------------

To identify genes regulated by *miR-455-5p* and *miR-455-3p*, we used *in silico* analyses and genome-wide gene expression analysis, as described previously \[[@R29], [@R42], [@R43]\]. We used the TargetScanHuman 7.0 (August, 2015 release), TCGA, and OncoLnc databases to select and narrow down putative miRNA target genes \[[@R44]--[@R46]\]. An oligo microarray (Human Ge 60K; Agilent Technologies) was used for gene expression analysis. The microarray data were deposited into the GEO database (accession number: GSE106791).

Western blot analysis {#s4_7}
---------------------

Cells were harvested 48 h after transfection, and lysates were prepared. Immunoblotting was performed with anti-SKA1 antibodies (1:500 dilution, SAB2701430; Sigma-Aldrich, St. Louis, MO, USA) and anti-SKA3 antibodies (1:1,000 dilution, ab175951; Abcam, Cambridge, UK). Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (1:10,000 dilution, ab8245; Abcam) were used as an internal loading control. The procedures were described previously \[[@R29], [@R42], [@R43]\].

Luciferase reporter assays {#s4_8}
--------------------------

The partial wild-type sequence of the *SKA1* or *SKA3* 3′-UTR or that with deletion of the *miR-455-5p* and *miR-455-3p* target site was inserted between the *Sgf*I-*Pme*I restriction sites in the 3′-UTR of the *hRluc* gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The procedures were described previously \[[@R29], [@R42], [@R43]\].

Immunohistochemistry {#s4_9}
--------------------

Tissue specimens were incubated overnight at 4°C with anti-SKA3 antibodies (1:50 dilution, ab175951; Abcam). The procedures were described previously \[[@R29], [@R42], [@R43]\].

TCGA database analysis of RCC {#s4_10}
-----------------------------

To investigate the clinical significance of miRNAs and candidate target genes, we used TCGA cohort data based on RNA sequencing. Gene expression and clinical data were obtained from cBioportal and OncoLnc datasets (downloaded on November 15th, 2017).

Statistical analysis methods {#s4_11}
----------------------------

To analyze the relationships between two groups and the numerical values, we performed Mann-Whitney *U*-tests and paired *t*-tests. Spearman\'s rank test was performed to evaluate the correlation between the two groups. Relationships among more than three variables and numerical values were analyzed using Bonferroni-adjusted Mann-Whitney *U*-tests. Disease-free and overall survival were analyzed using the Kaplan--Meier method, and multivariable Cox hazard regression analyses with JMP software (version 13; SAS Institute Inc., Cary, NC, USA). Other analyses were performed using Expert StatView (version 5; SAS Institute Inc.).

SUPPLEMENTARY MATERIALS AND FIGURES {#s5}
===================================
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